GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...

These Stocks Moved Moving the Most Today: Dayforce, Novo Nordisk, GoodRx, UnitedHealth, Sunrun, Duolingo, TeraWulf, and More ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk said it would begin selling its Type 2 diabetes treatment Ozempic directly to consumers at $499 per month, half ...